TableS3 League table

TableS3(a) Matrix of pairwise comparisons of regmins on change of LVEF% in subgroup of patients with CVD alone
(shown as standard mean difference and 95% confidence intervals).

	A	B	C
SCURA(%)			
A	0	-1.65 (-2.81,-0.49)	-0.73 (-2.23,0.77)
B Placebo	1.65 (0.49,2.81)	0	0.92 (-0.02,1.86)
C	0.73 (-0.77,2.23)	-0.92 (-1.86,0.02)	0

Abbre：A GLP-1RA, B Placebo, C SGLT-2i

TableS3(b) Matrix of pairwise comparisons of regimens on change of LVEF% in subgroup of patients with CVD and T2DM
(shown as standard mean difference and 95% confidence intervals).

	B	D	A	C
SCURA(%)				
B	0	-0.25 (-0.85,0.34)	-0.43 (-1.14,0.28)	-0.42 (-0.89,0.06)
D	0.25 (-0.34,0.85)	0	-0.07 (-0.87,0.72)	-0.16 (-0.92,0.60)
A	0.43 (-0.28,1.14)	0.07 (-0.72,0.87)	0	0.01 (-0.51,0.54)
C Placebo	0.42 (-0.06,0.89)	0.16 (-0.60,0.92)	-0.01 (-0.54,0.51)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

TableS3(c) Matrix of pairwise comparisons of regimens on change of E/e' in subgroup of patients with CVD and T2DM
(shown as standard mean difference and 95% confidence intervals).

	D	A	B	C
SCURA(%)				
D	0	0.01 (-0.60,0.62)	0.53 (-0.05,1.11)	0.43 (0.06,0.79)
A	-0.01 (-0.62,0.60)	0	0.52 (-0.32,1.36)	0.42 (-0.29,1.13)
B	-0.53 (-1.11,0.05)	-0.52 (-1.36,0.32)	0	-0.10 (-0.55,0.35)
C Placebo	-0.43 (-0.79,-0.06)	-0.42 (-1.13,0.29)	0.10 (-0.35,0.55)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

Table S3(d) Matrix of pairwise comparisons of regimens on change of LVESV in subgroup of patients with CVD and T2DM
(shown as standard mean difference and 95% confidence intervals).

	A	C	B
SCURA(%)			
A	0	0.15 (-0.17,0.47)	0.33 (0.04,0.61)
C	-0.15 (-0.47,0.17)	0	0.18 (-0.02,0.37)
B Placebo	-0.33 (-0.61,-0.04)	-0.18 (-0.37,0.02)	0

Abbre：A GLP-1RA, B Placebo, C SGLT-2i

Table S3(e) Matrix of pairwise comparisons of regimens on change of LVEDV in subgroup of patients with CVD and T2DM
(shown as standard mean difference and 95% confidence intervals).

	B	D	C	A
SCURA(%)				
B	0	0.09 (-0.33,0.52)	0.23 (-0.12,0.59)	0.37 (-0.24,0.99)
D	-0.09 (-0.52,0.33)	0	0.14 (-0.09,0.37)	0.28 (-0.27,0.83)
C Placebo	-0.23 (-0.59,0.12)	-0.14 (-0.37,0.09)	0	0.14 (-0.36,0.64)
A	-0.37 (-0.99,0.24)	-0.28 (-0.83,0.27)	-0.14 (-0.64,0.36)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

Table S3(f) Matrix of pairwise comparisons of regimens on change of SBP in subgroup of patients with CVD and T2DM
(shown as standard mean difference and 95% confidence intervals).

	A	D	B	C
SCURA(%)				
A	0	0.93 (0.44,1.43)	0.64 (0.03,1.25)	-0.24 (-1.04,0.57)
D	-0.93 (-1.43,-0.44)	0	0.12 (-0.32,0.56)	0.41 (0.15,0.67)
B	-0.64 (-1.25,-0.03)	-0.12 (-0.56,0.32)	0	0.29 (-0.22,0.80)
C Placebo	0.24 (-0.57,1.04)	-0.41 (-0.67,-0.15)	-0.29 (-0.80,0.22)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

Table S3(g) Matrix of pairwise comparisons of regmins on change of NT-pro BNP in subgroup of patients with CVD alone
(shown as standard mean difference and 95% confidence intervals).

	A	B	C
SCURA(%)			
A	0	0.30 (-0.17,0.77)	0.54 (-0.08,1.17)
B Placebo	-0.30 (-0.77,0.17)	0	0.25 (-0.16,0.65)
C	-0.54 (-1.17,0.08)	-0.25 (-0.65,0.16)	0

Abbre：A GLP-1RA, B Placebo, C SGLT-2i

Table S3(h) Matrix of pairwise comparisons of regmins on change of 6MWT in subgroup of patients with CVD alone
(shown as standard mean difference and 95% confidence intervals).

	A	C	B
SCURA(%)			
A	0	-0.86 (-2.68,0.97)	-1.31 (-2.95,0.33)
C	0.86 (-0.97,2.68)	0	-0.45 (-1.26,0.35)
B Placebo	1.31 (-0.33,2.95)	0.45 (-0.35,1.26)	0

Abbre：A = GLP-1RA, B = Placebo, C = SGLT-2i

TableS3(i) Matrix of pairwise comparisons of regimens on change of e' in overall population
(shown as standard mean difference and 95% confidence intervals).

	A	D	C	B
SCURA(%)				
A	0	-2.96 (-4.24,-1.68)	-3.82 (-4.72,-2.92)	-4.24 (-5.22,-3.27)
D	2.96 (1.68,4.24)	0	-0.86 (-1.77,0.05)	-1.28 (-2.27,-0.30)
C Placebo	3.82 (2.92,4.72)	0.86 (-0.05,1.77)	0	-0.43 (-0.81,-0.04)
B	4.24 (3.27,5.22)	1.28 (0.30,2.27)	0.43 (0.04,0.81)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

Table S3(j) Matrix of pairwise comparisons of regimens on change of E/e' in overall population
(shown as standard mean difference and 95% confidence intervals).

	A	D	B	C
SCURA(%)				
A	0	5.56 (-2.48,13.60)	5.78 (0.60,10.95)	5.97 (1.59,10.35)
D	-5.56 (-13.60,2.48)	0	6.07 (-2.05,14.19)	6.26 (-1.38,13.90)
B	-5.78 (-10.95,-0.60)	-6.07 (-14.19,2.05)	0	0.19 (-2.60,2.98)
C Placebo	-5.97 (-10.35,-1.59)	-6.26 (-13.90,1.38)	-0.19 (-2.98,2.60)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

Table S3(k) Matrix of pairwise comparisons of regimens on change of E/A in overall population
(shown as standard mean difference and 95% confidence intervals).

	A	D	C	B
SCURA(%)				
A	0	-2.97 (-6.92,0.98)	-1.84 (-3.96,0.28)	-2.57 (-5.17,0.04)
D	2.97 (-0.98,6.92)	0	-2.06 (-5.77,1.65)	-2.78 (-6.79,1.22)
C Placebo	1.84 (-0.28,3.96)	2.06 (-1.65,5.77)	0	-0.73 (-2.24,0.79)
B	2.57 (-0.04,5.17)	2.78 (-1.22,6.79)	0.73 (-0.79,2.24)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

Table S3(l) Matrix of pairwise comparisons of regimens on change of SBP in overall population
 (shown as standard mean difference and 95% confidence intervals).

	A	D	B	C
SCURA(%)				
A	0	0.00 (-0.33,0.33)	0.46 (-0.20,1.13)	0.40 (-0.13,0.93)
D	-0.00 (-0.33,0.33)	0	-0.28 (-1.06,0.49)	0.12 (-0.34,0.58)
B	-0.46 (-1.13,0.20)	0.28 (-0.49,1.06)	0	0.40 (-0.22,1.02)
C Placebo	-0.40 (-0.93,0.13)	-0.12 (-0.58,0.34)	-0.40 (-1.02,0.22)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

TableS3(m) Matrix of pairwise comparisons of regimens on change of NT-pro BNP in overall population
(shown as standard mean difference and 95% confidence intervals).

	D	B	C	A
SCURA(%)				
D	0	-0.14 (-0.94,0.66)	-0.14 (-0.87,0.60)	0.28 (-0.49,1.04)
B	0.14 (-0.66,0.94)	0	0.00 (-0.31,0.32)	0.14 (-0.43,0.71)
C Placebo	0.14 (-0.60,0.87)	-0.00 (-0.32,0.31)	0	0.14 (-0.33,0.62)
A	-0.28 (-1.04,0.49)	-0.14 (-0.71,0.43)	-0.14 (-0.62,0.33)	0

Abbre：A DDP-4i, B GLP-1RA, C Placebo, D SGLT-2i

TableS3(n) Matrix of pairwise comparisons of regimens on change of 6MWT in overall population
(shown as standard mean difference and 95% confidence intervals).

	A	C	B
SCURA(%)			
A	0	-1.18 (-2.74,0.38)	-1.52 (-2.76,-0.29)
C	1.18 (-0.38,2.74)	0	-0.34 (-1.30,0.61)
B Placebo	1.52 (0.29,2.76)	0.34 (-0.61,1.30)	0

Abbre：A GLP-1RA, B Placebo, C SGLT-2i

Note: Abbre: abbreviations; **e'**: early diastolic velocity; **E/e'**: mitral inflow E velocity to tissue doppler e' ratio; **E/A**: early diastolic to late diastolic velocities ratio**; CVD**: cardiovascular disease; **DPP-4i**: dipeptidyl peptidase-4 inhibitor; **GLP-1RA**: glucagon-like peptide-1 receptor agonist; **LVEDD**: left ventricular end-diastolic diameter; **LVEDV**: LV end-diastolic volume; **LVEF**: LV ejection fraction; **LVESD**: LV end-systolic diameter; **LVESV**: LV end-systolic volume; **LVMI**: LV mass index; **NT-pro BNP**: immunoreactive amino-terminal pro-brain natriuretic peptide; **SBP**: systolic blood pressure; **SGLT-2i**: sodium glucose cotransporter type 2 inhibitor; **T2DM**: type 2 diabetes; **6MWT**: 6-min walk test.